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The predictability of patency of the infarct· related artery assessed 
by means of three noninvasive easily obtainable markers was 
prospectively examined in 82 patients undergoing thrombolysis 
for their first myocardial infarction. Positive noninvasive markers 
were defined as follows: 1) early peak creatine kinase (CK) activity 
:512 h after the start of thrombolysis; 2) ;:::50% reduction in ST 
segment elevation; and 3) occurrence of reperfusion arrhythmias 
within the 1st 90 min of thrombolytic therapy. 
In 63 (77%) of the 82 patients, Thrombolysis in Myocardial 
Infarction (TIMI) grade IIIIII reperfusion was achieved within the 
1st 90 min as assessed by coronary angiography. Separate analysis 
of each marker revealed the following respective values for 
sensitivity, specificity and positive and negative predictive value 
regarding prediction of coronary artery patency: CK peak :512 h: 
84 %, 95 %, 98 % and 64 %; reduction of the ST segment elevation 
Over the last few years, intravenous thrombolysis has be-
come the standard therapeutic approach for patients with 
myocardial infarction. The reduction in short- and long-term 
mortality rates caused by thrombolytic therapy was demon-
strated in several large scale clinical trials (1-6). With 
intravenous administration of newer thrombolytic agents, 
coronary artery patency rates of 70% to 80% have been 
reported (7-11). 
It was recently shown (12,13) that immediate coronary 
angioplasty offers no clear advantage over delayed elective 
angioplasty in patients with initially successful thrombolysis. 
Conversely, patients with a persistently occluded infarct-
related artery may benefit from invasive interventions (14). 
To date, however, reliable determination of the reperfusion 
status is only possible by means of coronary angiography. 
The following noninvasive markers of reperfusion are 
currently under debate: 1) normalization of ST segment 
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;:::50%: 60%, 95%, 97% and 42%; and reperfusion arrhythmias: 
63%,89%,95% and 43%. 
The combined analysis of all three markers utilizing a logistic 
regression procedure showed that CK peak (p = 0.0001) and 
resolution of the ST segment elevation (p = 0.005), but not the 
occurrence of reperfusion arrhythmias (p = 0.26), were indepen. 
dent predictors of vessel patency. From this logistic regression 
procedure, a sensitivity of 100%, a specificity of 90%, a positive 
predictive value of 97% and a negative predictive value of 100% 
for prediction of coronary artery patency were obtained. Thus, 
the combined analysis of three noninvasive markers permits 
accurate prediction of coronary artery patency in patients with 
acute myocardial infarction undergoing thrombolytic therapy. 
(J Am Coli CardioI1991;18:44-9) 
elevation (15-17); 2) reperfusion arrhythmias (18-22); 3) 
time course of serum creatine kinase (CK) activity (23-25); 
and 4) resolution of infarct-related angina pectoris (26,27). 
However, in trials investigating only a single marker, pre-
dictability of reperfusion proved to be clinically insufficient. 
Only two studies (26,27) attempted to assess the predictive 
accuracy of combined analysis of different markers at the 
same time. Concerning ST segment and arrhythmia analysis, 
both studies (26,27) reported only the results of single 
electrocardiographic (ECG) recordings and observations 
made by study nurses, respectively. Determination of car-
diac enzyme release was not considered in either of these 
studies (26,27). 
The present prospectively designed study aimed to com-
pare the predictive power ofthe first three described mark-
ers in a given patient and to test the hypothesis that 
combinations of these markers may yield improved accuracy 
of noninvasive prediction of coronary artery patency. 
Methods 
Study patients. Eighty-two consecutive patients with 
their first myocardial infarction undergoing thrombolytic 
therapy were prospectively included in the study between 
1988 and 1990 at the University Hospital of Freiburg, 
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Freiburg, Germany. All patients gave informed consent to 
the study, which had been approved by the Ethics Commit-
tee of the University of Freiburg. Patients with typical chest 
pain of 2::30 min duration and ECG ST segment elevation 
2::0.1 m V in at least two limb leads or 2::0.2 m V in at least two 
precordial leads were eligible for the study. Symptoms and 
signs were not relieved by sublingual nitroglycerin. Throm-
bolytic therapy had to be started within 6 h after onset of 
symptoms. The thrombolytic agent used was pro-urokinase 
in 47 patients (combined with low dose urokinase in 14 of the 
47, anisoylated plasminogen streptokinase activator com-
plex (APSAC) in 27 patients, recombinant tissue type plas-
minogen activator (rt-PA) in 5 patients and urokinase in 3 
patients. After thrombolysis, all patients received an intra-
venous bolus injection of 7,500 to 10,000 IV of heparin, 
followed by a continuous infusion of 1,250 IV/h for the next 
72 to 96 h (partial thromboplastin time adjusted to two times 
the normal upper limit). 
The following exclusion criteria were applied: ongoing 
anticoagulant therapy, severe uncontrolled arterial hyper-
tension (systolic pressure >200 mm Hg or diastolic pressure 
> 120 mm Hg), peptic ulceration during the last year, recent 
history of surgery, history of coronary artery bypass grafting 
and no informed consent to participate in the study. Finally, 
patients with left bundle branch block or atrial fibrillation 
were excluded. 
Invasive studies. In all patients, coronary angiography 
was performed 60 to 90 min after onset of thrombolytic 
therapy and repeated 24 h later. The angiographic findings 
were assessed according to the Thrombolysis in Myocardial 
Infarction (TIMI) criteria for reperfusion (8). A TIMI grade 
II or III was defined as successful reperfusion. For statistical 
analysis, only early coronary artery patency within the 1st 
90 min was considered successful coronary artery opening. 
Holter ECG monitoring. Holter ECG monitoring for anal-
ysis of arrhythmias and the ST segment was started before 
initiation of thrombolytic therapy utilizing a commercially 
available two channel Cardio-Data Pacerecorder system. 
Bipolar electrodes were placed according to modified lead 
V 5 and a VF positions. Recordings were played back on a 
fully digitized AM-modulated (28) computer analysis system 
(Cardio-Data Mk 4). The ST segment was continuously 
analyzed by measuring values at isoelectric, junction and ST 
set points (80 ms after the J point) every 60 s. These standard 
set points of ST segment analysis were manually corrected 
after start of the analysis when necessary. Resolution of ST 
segment elevation was further documented by printouts 
(paper speed 25 mmls). 
Arrhythmias were first analyzed automatically, then ver-
ified by two independent investigators utilizing a 24 h two 
channel full disclosure and finally classified as follows: 1) 
single ventricular premature beat; 2) ventricular pairs; 3) 
ventricular bigeminy; 4) ventricular tachycardia (rate> 100 
beats/min); 5) slow ventricular tachycardia (rate <100 beats/ 
min, short coupling interval and irregular configuration and 
rate) (20); 6) accelerated idioventricular rhythm (rate <100 
beats/min, long coupling interval, regular configuration and 
rate and termination by sinus escape) (20); and 7) sinus 
bradycardia <55 beats/min detected from the heart rate 
histogram and confirmed by 25 mm/s strips. Arrhythmia and 
ST segment analysis were done by an investigator who was 
not aware of coronary artery patency at 90 min in each 
patient. 
Determination of CK. Blood samples were taken at 4 h 
intervals for the first 24 h and at 8 h intervals thereafter for 
determination of CK activity. Plasma total CK activity was 
assayed by the method of Rosalki (29). 
Definition of positive markers of coronary artery patency. 
Maximal CK activity within 12 h after the start of throm-
bolytic therapy was considered a positive marker of infarct-
related artery patency. This value was derived as the best 
cutoff point from an earlier study conducted at our institu-
tion (30). A positive ST marker was defined as a reduction in 
ST segment elevation of 2::50% within 90 min after the start 
of thrombolysis (15). Occurrence of an accelerated idioven-
tricular rhythm (18,22) or sinus bradycardia <55 beats/min 
(18,21) (the latter only in the setting of inferior myocardial 
infarction) within the 1 st 90 min was also predefined as a 
positive marker of reperfusion. 
Statistics. Values are reported as mean values ± SD. The 
calculation of sensitivity, specificity and positive predictive 
value and negative predictive value was performed accord-
ing to the following formulas. 
Sensitivity. Number of patients with reperfusion and 
positive reperfusion criteria/number of patients with reper-
fusion. 
Specificity. Number of patients without reperfusion and 
with negative reperfusion criteria/number of patients without 
reperfusion. 
Positive predictive value. Number of patients with reper-
fusion and positive reperfusion criteria/number of patients 
with positive reperfusion criteria. 
Negative predictive value. Number of patients without 
reperfusion and with negative reperfusion criteria/number of 
patients with negative reperfusion criteria. 
A chi-square test was used to test the correlation of each 
single marker with coronary artery patency. With coronary 
artery patency as the outcome variable, a logistic regression 
procedure was performed to test individually the strength of 
the association between coronary artery patency and each ~f 
the markers and to establish a statistical model for noninva-
sive assessment of reperfusion. Significance was considered 
at a p value :50.05. 
Results 
CUnical data. Eighty-two consecutive patients were in-
cluded in the study. There were 67 men and 15 women with 
a mean age of 58 ± 12 years (range 32 to 84). Forty-six 
patients suffered from acute anterior and 36 from inferior 
infarction. Time from onset of pain to initiation of thrombol-
ysis averaged 182 ± 80 min. In 63 patients (77%), TIMI grade 
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Table 1. Sensitivity, Specificity and Positive and Negative 
Predictive Value of Single Markers With Respect to a Patent 
Infarct-Related Artery 
Predictive Value 
Sensitivity Specificity 
(%) 
(%) (%) Positive Negative 
Single marker 
CK peak :512 h 84 95 98 64 
ST elevation reduction 60 95 97 42 
;:?:50% 
Reperfusion 63 89 97 43 
arrhythmias 
Combined analysis 
CK peak + ST 100 90 97 100 
elevation reduction 
+ reperfusion 
arrhythmias 
CK peak + ST elevation 97 90 95 90 
reduction 
The lower part of the table depicts the results of the multiple logistic 
regression procedure for the combined analysis of markers. CK = creatine 
kinase. 
II or III patency of the infarct-related artery was docu-
mented angiographically within the 1st 90 min. In 19 patients 
(23%), the infarct-related artery remained occluded for the 
1st 90 min. During the 1st 90 min of thrombolytic therapy, 
only five patients received an intravenous bolus injection of 
lidocaine (100 mg). No other local anesthetic drug was 
administered. Twenty-six patients were treated with a beta-
adrenergic blocking agent. When these patients were com-
pared with the 56 patients not taking a beta-blocker there 
were no significant differences with respect to patient age, 
infarct location and coronary artery patency at 90 min in 
patients with anterior or inferior infarction. 
Time course ofCK release (Table 1). In 53 (84%) of the 63 
patients with a patent infarct-related artery, maximal CK 
activity occurred within 12 h. Eighteen of the 19 patients 
20 1-+- --
without coronary artery patency had a CK peak later than 
12 h. According to these values, sensitivity for prediction of 
coronary artery patency was 84% and specificity 95%. The 
mean value for peak creatine kinase activity in patients with 
an open infarct-related artery was 1,218 ± 843 Ulliter 
compared with 1,228 ± 928 U/liter in patients with a persis-
tently occluded vessel (p = NS). Time from initiation of 
thrombolytic therapy to maximal CK was 9.3 ± 5.5 h in 
patients with a patent infarct-related artery versus 22.5 ± 
7.2 h in patients with failed thrombolysis (p < 0.00001). 
ST segment analysis (Table 1). Fifty-three (65%) of the 82 
patients exhibited 2:: 1 mm of ST segment elevation in at least 
one ECG lead during Holter monitoring at the start of 
thrombolytic therapy. Thirty-eight (60%) of the 63 patients 
with a patent infarct-related artery demonstrated a reduction 
of 2::50% of the ST segment elevation at 90 min. In all other 
patients, no change or nonspecific minor changes were noted 
regardless of the reperfusion status. However, only one of 
the patients with a permanent occluded infarct-related artery 
showed significant resolution of the elevated ST segment. 
Resolution of ST segment elevation 2::50% within the 1st 
90 min was associated with successful reperfusion in 97% of 
all patients. Conversely, 58% of the patients with ST seg-
ment changes <50% had a patent infarct-related artery. 
Figure 1 shows a plot of sensitivity and specificity at various 
cutoff points of ST segment reduction. It is obvious that the 
predefined value of 50% ST segment resolution is well within 
an acceptable range for both. 
Reperfusion arrhythmias (Tables 1 and 2). The correla-
tion of several arrhythmia categories with coronary artery 
patency was statistically tested by chi-square analysis (Table 
2). Only accelerated idioventricular rhythm and sinus brady-
cardia in the setting of inferior myocardial infarction showed 
a significant correlation and were therefore included in 
further analysis. Both of these markers had also been 
predefined as positive reperfusion markers (see Methods). 
In 25 patients with a patent coronary artery, episodes of 
Figure 1. Sensitivity and specificity for prediction of 
coronary artery patency at various cutoff points of ST 
segment elevation reduction. 
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Table 2. Occurrence of Arrhythmias Within the 1st 90 Min After 
Onset of Thrombolytic Therapy and Correlation With Early 
Reperfusion of the Infarct-Related Artery 
TIMI Grade TIMI Grade 
WIll Oil 
Arrhythmias (n = 63) (n = 19) P Value 
AIVR 25 0.011 
Sinus bradycardia 18/25 1111 0.002 
Ventricular bigeminy 12 1 NS 
Slow VT 9 0 NS 
VT 9 NS 
VF 4 0 NS 
AIVR = accelerated idioventricular rhythm; TIMI = Thrombolysis in 
Myocardial Infarction trial; VF = ventricular fibrillation; VT = ventricular 
tachycardia. 
accelerated idioventricular rhythm were documented that 
varied in duration from 3 beats to 15 min. Eighteen patients 
with inferior infarction demonstrated sinus bradycardia; 3 of 
them also had accelerated idioventricular rhythm. Thus, 
reperfusion arrhythmias were observed in 40 (63%) of 63 
patients with documented patency of the infarct-related 
artery. Only one patient with inferior myocardial infarction 
and a permanent occluded right coronary artery exhibited 
sinus bradycardia. Overall, 95% of patients showing one of 
the defined reperfusion arrhythmias had a patent infarct-
related artery. However, 57% of patients without these 
reperfusion arrhythmias also had successful reperfusion, 
accounting for the low negative predictive value (Table 1). 
Combined analysis of ST segment, reperfusion arrhythmias 
and CK. To compare the strength of each noninvasive 
marker, the correlation of each marker with the coronary 
angiogram at 90 min was tested by means of chi-square 
analysis. All three markers correlated significantly with 
coronary artery patency. The p values were 0.00001 for early 
CK peak, 0.0001 for ST segment resolution and 0.001 for 
reperfusion arrhythmias. 
In the second step, combined analysis of the three mark-
ers was performed by means of a logistic regression proce-
dure (Table 1). The results indicated that maximal CK 
release within 12 h correlated with coronary artery patency 
(independently of the other markers) (p = 0.0001; regression 
coefficient 5.103; odds ratio 164.4). Resolution of the ST 
segment 2:50% within 90 min was also an independent 
predictor of coronary artery patency (p = 0.005; regression 
coefficient 3.731; odds ratio 41.7). Reperfusion arrhythmias 
did not independently correlate with an open infarct-related 
artery (p = 0.26; regression coefficient 1.403; odds ratio 4.1). 
From this logistic regression procedure, a prediction 
model was established. Categories of CK release, ST seg-
ment resolution and occurrence of reperfusion arrhythmias 
were characterized as ordinal variables (CK = 1, if the CK 
peak is :512 h, CK = 0 with a peak> 12 h; ST = 0 if the ST 
segment reduction after 90 min is <50%, or 1 if 2:50%; 
reperfusion arrhythmias = 1 if reperfusion arrhythmias 
are present, otherwise 0). Thus, if either the CK peaked at 
< 12 h or there was >50% reduction in ST segment elevation 
at 90 min or reperfusion arrhythmias, the infarct-related 
artery was likely to be open at 90 min after thrombolytic 
therapy. 
Discussion 
Reliable assessment of the coronary artery perfusion 
status of patients undergoing thrombolytic therapy for acute 
myocardial infarction would allow early appropriate triage of 
patients to invasive interventions. It was recently demon-
strated by Abbottsmith et al. (31) that rescue angioplasty is 
beneficial in patients whose infarct-related artery fails to 
reperfuse after thrombolysis. To date, only coronary angi-
ography is used to identify these patients. The present study 
indicates that the combined analysis of three noninvasive 
clinical markers that can be easily obtained predicts reper-
fusion status to a clinically useful degree. 
Creatine kinase (CK). Separate analysis of a single reper-
fusion marker is relatively insensitive and lacks specificity 
(26,27). Considering CK peak, a cutoff value of 12 h after the 
start of thrombolysis was derived from an earlier trial at our 
institution (30). In the present study, this criterion yielded a 
sensitivity of 84% and a specificity of 95%, values corre-
sponding to those reported by Katus et al. (25). A disadvan-
tage of using CK peak as a reperfusion marker is, of course, 
the fact that test results are only available hours after 
completion of myocardial necrosis. However, it has been 
recently demonstrated (24,32) that the time to peak CK 
activity can be substituted by the rapidity of the initial 
release of this enzyme within the 1st 90 to 120 min of 
thrombolytic therapy. The rapid analysis of myoglobin may 
offer additional advantages because of the earlier initial 
increase in this protein (25,33). 
ST segment elevation. With respect to ST segment anal-
ysis, Krucoff et al. (16), utilizing continuous Holter ECG 
monitoring in 46 patients, reported a specificity of 82% and a 
sensitivity of 89% for successful reperfusion of the infarct-
related artery. In our study, separate consideration of ST 
segment normalization, which had been predefined as a 
reduction in ST segment elevation of 2:50% (15), resulted in 
a sensitivity of only 60%. This finding is in agreement with 
the results reported by Kircher et al. (27), who found a 
sensitivity of 52% for the ST marker. In other studies 
(26,27), Holter monitoring for continuous analysis of the ST 
segment was replaced by surface ECG recordings before and 
90 to 120 min after the start of thrombolysis. However, using 
only occasional ECG recordings, the potential strength of ST 
segment analysis cannot be adequately judged. 
Reperfusion arrhythmias. The value of reperfusion ar-
rhythmias as a marker of coronary artery patency is still a 
matter of debate. Goldberg et al. (18) initially described sinus 
bradycardia in inferior infarction and accelerated idioven-
tricular rhythm as markers of reperfusion, a finding also 
reported by Gorgels et al. (22). Conversely, Gore et al. (23) 
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confirmed the usefulness of sinus bradycardia but did not 
find a correlation between accelerated idioventricular 
rhythm and coronary artery reperfusion. In the present trial, 
several arrhythmia categories were tested for their strength 
to predict coronary artery patency. From all categories 
examined, only accelerated idioventricular rhythm and sinus 
bradycardia in the setting of inferior myocardial infarction 
were significantly correlated with coronary artery patency as 
assessed by angiography. Thus, this result confirmed the 
predefinition of both of these markers in our study. 
Combined analysis of the three markers. In this study, 
prediction of coronary artery patency was improved by 
combined analysis of three noninvasive markers. Utilizing a 
logistic regression model, sensitivity and negative and posi-
tive predictive values ranged between 97% and 100%, with 
an acceptable specificity of 90%. From this logistic regres-
sion procedure, a simple model was derived, permitting 
reliable determination of the coronary artery patency in 
individual patients. The practical value of this model, how-
ever, needs verification in a prospective trial. To date, 
evaluation of combined analysis of several noninvasive 
perfusion markers has been performed in only two trials 
(26,27). Califf et al. (26) and Kircher et al. (27) used resolu-
tion of the ST segment, occurrence of reperfusion arrhyth-
mias and reduction in chest pain as reperfusion markers. In 
both studies (26,27), combined analysis of these markers did 
not yield better predictability. However, several limitations 
of these studies must be considered. Resolution of chest pain 
is influenced by the administration of nitrate and morphine 
derivatives. Neither study used Holter ECG monitoring, 
which provides more accurate representation of the potential 
utility of the ST segment and arrhythmias. Finally, no 
enzymatic reperfusion markers were considered. Whereas 
Califf et al. (26) in a multicenter study were unable to 
discriminate between success or failure of reperfusion, 
Kircher et al. (27) could predict perfusion status in 43% of 
their patients in whom all three markers were either present 
or absent. 
In the present study, predictability was also 100% in 
patients in whom all markers were present (n = 23) or absent 
(n = 16). However, by using the regression model, predic-
tion was also possible in the remaining patients. Because 
arrhythmias were not independently correlated with coro-
nary artery patency, the logistic regression model calculated 
only with CK peak and ST segment resolution yielded 
almost identical values for sensitivity (97%), specificity 
(90%) and positive (97%) and negative (90%) predictive 
value. 
Conclusions. This study indicates that the combined anal-
ysis of three noninvasive reperfusion markers enhances the 
predictability of coronary artery patency to a clinically 
useful degree. This combined analysis by logistic regression 
is clearly superior to separate analysis of each marker. The 
applicability of this model, however, must be evaluated in 
prospective trials. In future studies, the slope of the initial 
CK release curve within the 1st 90 min of therapy (24,32) 
should replace determination of the time of maximal release 
of this enzyme. 
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